Over the past 12‑18 months, the FSMP for Dietary Management of Preterm Infants and Low Weight Infants industry has witnessed a cascade of strategic moves that are reshaping the competitive landscape. In Q2 2023, NutriHealth partnered with MedTech’s neonatal monitoring unit to embed real‑time nutrient analytics into its leading preterm formula, accelerating data‑driven feeding protocols. Meanwhile, a €120 million acquisition of BabyNutri by GlobalPharma in August 2023 expanded the latter’s product portfolio and granted access to BabyNutri’s patented whey‑protein hydrolysate technology. Early 2024 saw the launch of a plant‑based, DHA‑enriched FSMP by GreenMoms, marking the first fully vegan offering approved under the EU’s revised Food for Special Medical Purposes directive, which tightened compositional reporting and post‑market surveillance. Consumer preference surveys indicate a 22 % rise in demand for clean‑label, allergen‑free formulas, prompting manufacturers to reformulate existing lines. Finally, a $45 million Series C round led by HealthVentures enabled NeonatalScience to scale its modular production facility in Singapore, positioning it to meet anticipated growth in Asia‑Pacific markets. These moves highlight the accelerating FSMP for Dietary Management of Preterm Infants and Low Weight Infants industry trends.
